Table 3.
PV B19-related pure red cell aplasia in adult kidney transplant recipients. Order by year of transplantation, if not given by year of publication. Search performed by PubMed website [18,23,25,38–60].
| Case no. | Age | Gender | IS | Treatment | Onset (weeks) | References |
|---|---|---|---|---|---|---|
| 1990–2000 | ||||||
| 1 | 34 | M | nd | IVIG | nd | 25 |
| 2 | 62 | M | TAC | IVIG | 56 | 18 |
| 3 | 47 | F | CsA/Cs | IVIG | 2 | 38 |
| 4 | 48 | M | ATG/CsA/Cs | IVIG | 2 | 39 |
| 5 | 57 | F | ATG/Tac/AZA/Cs | IVIG/ESA | 24 | 40 |
| 6 | 62 | M | CSa/AZA/Cs | IVIG | 6 | 41 |
| 7 | 38 | M | CsA/AZA/CS | IVIG | 4 | 41 |
| 8 | 43 | F | ATG/Tac/MMF/Cs | IVIG | 4 | 41 |
| 9 | 37 | M | TAC/MMF/Cs | IVIG | 4 | 42 |
| 10 | 61 | M | ATG/TAC/AZA/Cs | IVIG | 4 | 43 |
| 11 | 26 | F | TAC/AZA/Cs | IVIG/S | 3 | 44 |
| 12 | 46 | M | TAC/MMF/Cs | IVIG | 40 | 45 |
| 13 | 40 | F | TAC/MMF/Cs | IVIG | 4 | 45 |
| 14 | 43 | F | ATG/Tac/MMF/Cs | DEC/IVIG | 52 | 25 |
| 15 | 21 | M | nd | IVIG | 6 | 25 |
| 16 | 39 | M | CsA/MMF/Cs | IVIG | 2 | 46 |
| 2001–2018 | ||||||
| 17 | 39 | F | nd | DEC/IVIG | 6 | 25 |
| 18 | 26 | M | nd | IVIG/DEC | 5 | 25 |
| 19 | 40 | M | TAC/AZA/Cs | IVIG/S | 16 | 47 |
| 20 | 39 | M | TAC/AZA/Cs | IVIG/DEC | 6 | 48 |
| 21 | 50 | F | Tac/MMF/Cs | IVIG/DEC/S | 4 | 48 |
| 22 | 65 | M | Tac/MMF/Cs | DEC/ | 5 | 49 |
| 23 | 39 | M | BAS/MMF/SRL/Cs | IVIG/DEC | 9 | 50 |
| 24 | 34 | M | TAC/MMF/Cs | IVIG | 4 | 51 |
| 25 | 55 | F | nd | DEC/IVIG | 4 | 25 |
| 26 | 49 | M | Tac/MMF/Cs | DEC/IVIG | nd | 52 |
| 27 | 20 | F | TAC/MMF/Cs | S | 4 | 53 |
| 28 | 22 | F | CsA/MMF/Cs | S | 4 | 29 |
| 29 | 39 | F | TAC/MMF/Cs | DEC/IVIG | 40 | 54 |
| 30 | 28 | F | TAC/MMF/Cs | DEC/IVIG | 8 | 55 |
| 31 | 34 | F | TAC/MMF/Cs | S | 12 | Own case |
| 32 | 30 | F | nd | IVIG | 4 | 56 |
| 33 | 42 | F | TAC/AZA/Cs | IVIG | 158 | 57 |
| 34 | 30 | M | ATG/TAC/MMF/Cs | IVIG | 12 | 29 |
| 35 | 35 | M | BAS/TAC/MMF/Cs | DEC/S/IVIG | 6 | 23 |
| 36 | nd | M | TAC/MMF/Cs | DEC/IVIG | 7 | 23 |
| 37 | 40 | F | TAC/MMF/Cs | S | 36 | 59 |
| 38 | 30 | M | TAC/MMF/Cs | S | 8 | 59 |
| 39 | 35 | F | TAC/MMF/Cs | S | 160 | 59 |
| 40 | 18 | M | TAC/MMF/Cs | DEC/IVIG | 4 | 60 |
| 41 | 65 | M | TAC/MMF/Cs | IVIG | 8 | 21 |
| 42 | 44 | F | BAS/TAC/MMF/Cs | IVIG/DEC | 7 | 61 |
| 43 | 30 | M | BAS/TAC/MMF/Cs | IVIG/DEC | 11 | 61 |
| 44 | 58 | M | BAS/TAC/MMF/Cs | IVIG/DEC | 8 | 61 |
| 45 | 30 | M | TAC/MMF/Cs | DEC/S/IVIG | 8 | Own case |
| 46 | 28 | F | TAC/MMF/Cs | IVIG | 4 | 62 |
| 47 | 32 | M | TAC/MMF/Cs | IVIG | 9 | 62 |
| 48 | 49 | M | ATG/CsA/MMF/Cs | IVIG/DEC | 8 | 63 |
IS – initial immunosuppression regimen; onset – time to clinical symptoms of PV infection; DEC – decreased immunosuppression; IVIG – immunoglobulin; S – switch TAC to CsA.